Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes

Novo Nordisk A/S1,569 enrolled

Overview

This trial is conducted in Europe. The aim of this observational study is to evaluate the glycaemic control in patients with type 1 or 2 diabetes using NovoMix® 30 or Levemir® under normal clinical practice conditions.

Study Type

OBSERVATIONAL

Enrollment

1,569

Conditions

Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

Interventions

biphasic insulin aspart 30DRUG

Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation

insulin detemirDRUG

Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Levemir® above 6 yrs * NovoMix® 30 above 18 yrs * Patients with Type 1 or Type 2 diabetes, including newly diagnosed Exclusion Criteria: * Current treatment with NovoMix® 30 or Levemir®

Locations (1)

Novo Nordisk Investigational Site

Skopje, North Macedonia

Outcomes

Primary Outcomes

HbA1c

Time frame: at 24 weeks

Secondary Outcomes

FPG, PG profile, weight, % of subjects on target

Time frame: at 24 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.